Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-site, single-arm Phase 2 study of adjuvant nivolumab combined
with ipilimumab for the treatment of adult subjects with completely treated high-risk ocular
melanoma, as defined in eligibility criteria, without evidence of metastatic disease. All
patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus
ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks. Treatment will continue until disease
progression, unacceptable toxicity, patient request to discontinue or completion of
treatment. Subjects may receive up to 25 doses of nivolumab and 8 doses of ipilimumab